Aradigm Corporation Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2018
Aradigm Corporation announced unaudited consolidated earnings results for the first quarter ended March 31, 2018. For the quarter, the company reported revenues were $1,473,000 against $1,693,000 for the same period a year ago. Loss from operations was $3,809,000 against $2,759,000 for the same period a year ago. Net loss and comprehensive loss was $4,802,000 against $3,678,000 for the same period a year ago. Basic and diluted net loss per common share was $0.32 against $0.25 for the same period a year ago. The increase in net loss resulted primarily from an increase in operating expenses of $800,000 related to the FDA meeting in January and the submission of the MAA to EMA in March for approval of Linhaliq.